Core Insights - The Chinese medical insurance directory will undergo its largest expansion of innovative drugs in history starting January 1, 2026, adding 114 new drugs, including 50 class 1 innovative drugs, while removing 29 drugs that are either unavailable or can be replaced by better alternatives [1][2] - The total number of drugs in the directory will increase to 3,253, significantly enhancing coverage for key areas such as oncology, chronic diseases, mental health, rare diseases, and pediatric medications [1][2] - The inclusion of innovative drugs in the medical insurance directory reflects a strong commitment to support genuine innovation and differentiated innovation in the healthcare sector [1][2] Medical Insurance Directory Expansion - The new directory will include 114 drugs, with nearly 44% being class 1 innovative drugs, indicating a growing emphasis on innovative treatments [1][2] - The directory will enhance the insurance coverage for critical areas, improving access to necessary medications for patients [1][2] Innovative Drug Market Dynamics - The entry of innovative drugs into the medical insurance directory is a key driver for market growth, with those included typically experiencing rapid sales growth within a year [4] - Companies like Heng Rui Medicine and Innovent Biologics have successfully included multiple innovative products in the new directory, indicating a trend towards increased market access for innovative therapies [4][5] Clinical Needs and Treatment Options - The new directory addresses significant clinical needs, particularly in oncology, with new drugs targeting various types of cancers, thereby expanding treatment options for patients [9][10] - The inclusion of targeted therapies for conditions like severe asthma and breast cancer provides patients with more accessible and effective treatment options [6][10] Commercial Insurance Directory - The introduction of a commercial insurance directory for innovative drugs aims to balance clinical value, corporate profits, and the sustainability of insurance funds [2][12] - The commercial insurance directory includes 19 innovative drugs, highlighting a focus on high-value treatments that exceed basic insurance coverage [12][15] Policy and Regulatory Environment - Recent reforms in drug approval and medical insurance payment systems have created a conducive environment for the development of innovative drugs in China [17][18] - The acceleration of drug approvals and the establishment of a more rigorous evaluation system for innovative drugs are reshaping the landscape for pharmaceutical companies [17][18] Future Outlook - The ongoing expansion of the medical insurance directory signifies a shift towards making innovative drugs more accessible and affordable for the general population, enhancing overall healthcare outcomes [20][21] - The collaboration between policy, industry, and capital markets is essential for fostering high-quality development in the innovative drug sector [19][20]

新京报讯（记者王卡拉）作为连续八年参展的"全勤生"，阿斯利康在第八届中国国际进口博览会上延续 1000平方米的展台规模，全面展示了其在"推动科学与创新""促进诊疗变革与共同健康""支持可持续发 展"三大举措下的丰硕成果与坚定承诺。本届进博会，阿斯利康举办了30余场活动并宣布多项重磅投资 与合作，带来两款肿瘤创新药的中国首展，再次印证了其依托进博平台，深耕中国、与中国医疗健康产 业同频共振的长期决心。 今年进博会，阿斯利康首次展出了两款最新在华获批用于治疗乳腺癌的肿瘤创新药：荃科得（卡匹色替 片）和达卓优（注射用德达博妥单抗），预计未来五年将惠及16万余名中国乳腺癌患者。阿斯利康旗下 健康科技公司Evinova还与和铂医药达成战略合作，通过深度融合Evinova全球领先的临床试验AI平台与 和铂医药前沿的AI药物研发能力，加速下一代创新药物研发。 阿斯利康在肿瘤领域的探索不仅限于药物创新，更着眼于构建覆盖"筛、诊、治、管"全链路的全病程管 理模式。借助进博会平台，阿斯利康联合临床专家等共同发起前列腺癌早筛公益科普行动，呼吁社会提 升"早筛、早诊、早治"的健康意识，助力前列腺癌防治关口前移。在精准诊断方面，阿斯利 ...